Education
About Us
Working with TipRanks
Follow Us
Nkarta (NKTX)
NASDAQ:NKTX
NKTX Stock Chart & Stats
$2.01
-$0.05(-2.07%)
At close: 4:00 PM EST
$2.01
-$0.05(-2.07%)
Day’s Range― - ―
52-Week Range$1.31 - $2.74
Previous CloseN/A
Volume369.36K
Average Volume (3M)612.23K
Market Cap
$142.06M
Enterprise Value$156.45M
Total Cash (Recent Filing)$282.33M
Total Debt (Recent Filing)$76.63M
Price to Earnings (P/E)―
Beta0.90
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding71,029,510
10 Day Avg. Volume602,298
30 Day Avg. Volume612,228
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.62
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.53
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Data Integration Across StudiesAbility to pool data from the two trials supports more robust dose-escalation analyses and may shorten the time to identify optimal dosing for multiple indications.
Regulatory And Trial DesignAgreement with the regulator to remove patient-by-patient stagger and permit a 3+3 dose-escalation framework enables simultaneous enrollment within cohorts, which can accelerate dose-finding milestones.
Safety Oversight ConsolidationCombining both studies under a single independent Data and Safety Monitoring Board centralizes safety review and can speed unified decisions on dose escalation and protocol adjustments.
Bears Say
Conditioning Regimen ChallengesShift to a fludarabine/cyclophosphamide conditioning regimen was prompted by prior incomplete B-cell depletion, indicating earlier protocol limitations that may complicate efficacy interpretation and require further adjustments.
Financial Performance PressureA reported quarterly net loss underscores ongoing operating losses that could heighten funding needs or dilute valuation if additional capital is required.
Safety SignalsReports of deep B-cell aplasias in patients create material safety concerns that could lead to increased monitoring, protocol modifications, or regulatory attention.
Nkarta News
NKTX FAQ
What was Nkarta’s price range in the past 12 months?
Nkarta lowest stock price was $1.31 and its highest was $2.74 in the past 12 months.
What is Nkarta’s market cap?
Nkarta’s market cap is $142.06M.
When is Nkarta’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nkarta’s earnings last quarter?
Currently, no data Available
Is Nkarta overvalued?
According to Wall Street analysts Nkarta’s price is currently Overvalued.
Does Nkarta pay dividends?
Nkarta does not currently pay dividends.
What is Nkarta’s EPS estimate?
Nkarta’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nkarta have?
Nkarta has 71,029,510 shares outstanding.
What happened to Nkarta’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nkarta?
Currently, no hedge funds are holding shares in NKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nkarta Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
NKTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 92.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $65.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.96%
12-Months-Change
Fundamentals
Return on Equity
-26.69%
Trailing 12-Months
Asset Growth
-19.70%
Trailing 12-Months
Company Description
Nkarta
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Technical Analysis
Ownership Overview
Currently, No data available
---